Table 2.
Treatment course and outcome in the fluoroquinolone and nonfluoroquinolone groups
| Fluoroquinolone (n = 43) | Nonfluoroquinolone (n = 34) | P value | |
|---|---|---|---|
| ICU admission to TB study (days) | 1.7 ± 5.9 | 5.6 ± 15.1 | 0.13 |
| TB study in the ICU within 1 week | 39 (91) | 28 (82) | 0.46 |
| Died before ATT was begun | 4 (9) | 9 (27) | 0.05 |
| Initiation of ATT in the ICU within 2 weeks | 11 (29) | 7 (29) | >0.99 |
| Length of ICU stay (days) | 30.0 ± 20.5 | 17.5 ± 17.9 | <0.01 |
| Nonsurvivors in the ICU | 27.0 ± 18.0 | 22.0 ± 25.0 | 0.27 |
| Survivors in the ICU | 31.0 ± 21.6 | 16.0 ± 14.0 | 0.03 |
| Intubation period (days) | 38.6 ± 61.5 | 19.5 ± 24.0 | 0.09 |
| Nonsurvivors in the ICU | 28.0 ± 18.35 | 25.0 ± 29.2 | 0.13 |
| Survivors in the ICU | 43.0 ± 71.5 | 16.9 ± 21.4 | <0.01 |
| Length of hospital stay(days) | 71.2 ± 62.7 | 38.4 ± 25.5 | <0.01 |
| Nonsurvivors in the hospital | 42.0 ± 28.0 | 37.0 ± 26.41 | 0.83 |
| Survivors in the hospital | 81.0 ± 63.3 | 40.0 ± 25.4 | <0.01 |
| 100-day mortality rate | 17 (40) | 23 (68) | 0.02 |
Data presented as n (%) or mean ± standard deviation. ATT, anti-tuberculosis treatment; TB, tuberculosis.